Crisaborole
CAS: 906673-24-3
Ref. 3D-FC166718
| 25mg | 136.00 € | ||
| 50mg | 192.00 € | ||
| 100mg | 283.00 € | ||
| 250mg | 406.00 € | ||
| 500mg | 639.00 € |
Product Information
- AN27284-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile
- 4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile
- 4-[(1-Hydroxy-1,3-dihydro-2,1-benzoxaborol-5-yl)oxy]benzonitrile
- An 2728
- An2728
- Benzonitrile, 4-[(1,3-dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]-
- Eucrisa
- Staquis
Crisaborole is a topical antimicrobial peptide that was approved by the FDA in 2017 for the treatment of mild to moderate atopic dermatitis and eczema. It belongs to a class of drugs called small-molecule inhibitors of phosphodiesterase 4 (PDE4). PDE4 is an enzyme that hydrolyzes cyclic adenosine monophosphate (cAMP) and thereby reduces the levels of cAMP in cells. Crisaborole binds to the PDE4 enzyme and blocks its activity, leading to an increase in the level of cAMP. This increased concentration of cAMP leads to suppression of inflammation, which is a major symptom associated with skin diseases such as dermatitis and eczema.
Crisaborole has shown low toxicity in vivo studies on human volunteers. In a study involving administration of crisaborole at doses up to 300 mg/day for 14 days, adverse events were reported by 3% patients, with no serious adverse
Chemical properties
Technical inquiry about: 3D-FC166718 Crisaborole
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
